Background
Phase 3, open-label, randomized 1:1, 80 centers in China. N=497. Recurrent/metastatic ESCC progressing after 1L PD-1/PD-L1 inhibitor + platinum chemotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) = EGFR x HER3 bispecific ADC with topoisomerase I inhibitor payload (Ed-04).
Results
Interventions and follow up: Arm A: iza-bren 2.5 mg/kg IV d1, d8 q3w (n=249)
Arm B: physician's choice chemo q3w: irinotecan, paclitaxel or docetaxel (n=248)
Primary endpoint: dual: PFS (BICR, RECIST 1.1) and OS
mFollow up: NR (interim analysis; final follow-up Oct 17, 2025)
Results: PFS (BICR): 4.17 vs 1.97 mo; HR 0.50 (95% CI 0.40-0.63); P<.001
OS: 9.79 vs 7.20 mo; HR 0.63 (0.48-0.82); P<.001
ORR: 35.3% vs 13.1% (ASCO 2026 presentation)
DCR: 74.3% vs 45.5%
Arm B: physician's choice chemo q3w: irinotecan, paclitaxel or docetaxel (n=248)
Primary endpoint: dual: PFS (BICR, RECIST 1.1) and OS
mFollow up: NR (interim analysis; final follow-up Oct 17, 2025)
Results: PFS (BICR): 4.17 vs 1.97 mo; HR 0.50 (95% CI 0.40-0.63); P<.001
OS: 9.79 vs 7.20 mo; HR 0.63 (0.48-0.82); P<.001
ORR: 35.3% vs 13.1% (ASCO 2026 presentation)
DCR: 74.3% vs 45.5%
Adverse events
Grade ≥3 TRAEs: 85.1% vs 59.3%
Hematologic: predominant grade ≥3 toxicity (cytopenias); individual rates NR in abstract
ILD: all-grade 1.6% vs 0.4%; G≥3 0.8% vs 0%
Discontinuation (TRAE): 2.0% with iza-bren
Hematologic: predominant grade ≥3 toxicity (cytopenias); individual rates NR in abstract
ILD: all-grade 1.6% vs 0.4%; G≥3 0.8% vs 0%
Discontinuation (TRAE): 2.0% with iza-bren
Conclusions
Iza-bren significantly improved both PFS and OS over single-agent chemotherapy in ESCC after 1L chemo-immunotherapy. It is the first agent to show an OS benefit in the post-IO second-line ESCC setting, at the cost of substantial (mainly hematologic) grade ≥3 toxicity.
Key Limitations
Open-label; interim analysis with short absolute gains (PFS +2.2 mo, OS +2.6 mo); China-only population (Asian ESCC), so generalizability to Western patients is uncertain; weak control arm (median PFS ~2 mo with single-agent chemo); 85% grade ≥3 TRAEs needs d1/d8 schedule and close count monitoring; no biomarker (EGFR/HER3) selection data reported; no QoL data in abstract.
Clinical Context
After 1L chemo-IO, standard 2L ESCC options are single-agent taxane or irinotecan (ICI-rechallenge not supported), with ~2 mo PFS. Iza-bren was approved by China's NMPA in Jul 2026 for R/M ESCC after platinum chemo + PD-1/PD-L1 inhibitor (its second China approval, after nasopharyngeal carcinoma). Not FDA/EMA approved; not yet in NCCN/ESMO guidelines. Global trials (BMS partnership) are needed to confirm benefit outside China.
